India’s pharma industry growth to drive $130 billion market by 2030

India’s pharmaceutical industry is poised for significant expansion, with the domestic market projected to grow from the current $60 billion to $130 billion by 2030, reflecting its rising global stature and strong policy support.According to an official factsheet released on Saturday, India’s pharma sector ranks third globally by volume and 11th by value, underlining its scale and competitiveness in the global healthcare ecosystem.The industry comprises over 3,000 companies and more than 10,500 manufacturing units, showcasing a robust and expanding production base. As per the Economic Survey 2025-26, the sector recorded an annual turnover of Rs4.72 lakh crore in FY25, driven by steady domestic demand and strong export performance.
Pharmaceutical exports have grown at a compound annual growth rate (CAGR) of 7% over the past decade, highlighting consistent global demand for Indian medicines. India continues to dominate the global generics market, supplying nearly 20% of the world’s generic drugs and manufacturing around 60,000 generic brands across 60 therapeutic categories.The sector’s growth trajectory has been supported by strong manufacturing capabilities, rising foreign investment, and targeted government initiatives aimed at boosting domestic production and reducing import dependence. These measures have also helped strengthen India’s position in global supply chains.India’s pharmaceutical ecosystem is further bolstered by high regulatory standards and global trust. The country has the highest number of manufacturing plants approved by the United States Food and Drug Administration outside the United States, reflecting confidence in the quality and safety of Indian medicines.
In addition, India plays a crucial role in the global vaccine supply chain. It meets 40–70% of global demand for DPT and BCG vaccines and accounts for 90% of measles vaccine requirements of the World Health Organization. Indian manufacturers also supply nearly 60% of vaccines to UNICEF.The country is also a key player in the active pharmaceutical ingredients (API) segment, with around 500 manufacturers contributing nearly 8% to the global API industry.Looking ahead, proposed and recently concluded trade agreements with regions such as the European Union, the United Kingdom, and New Zealand are expected to further boost the sector by improving market access and strengthening trade linkages.
Pharmaceutical exports stood at $30.5 billion in 2024–25, marking a nearly 16-fold increase from $1.9 billion in 2000–01, highlighting the sector’s deepening integration into global healthcare supply chains and its growing role as a reliable partner in the global pharmaceutical landscape.